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Recent studies have implicated B cells in atherosclerosis and have verified the atheroprotective 
effect of rituximab. Rituximab is widely used for desensitization in ABO-incompatible or crossmatch-
positive kidney transplantation (KT). Using a single-center KT database, we performed propensity-
matched analysis to investigate the association between rituximab and posttransplant atherosclerotic 
cardiovascular disease (ASCVD). Among 1299 eligible patients, 239 given rituximab induction were 
matched with 401 controls in a 1:2 propensity score matching process. The cumulative rate of ASCVD 
during 8 years of follow-up was significantly lower in rituximab-treated patients, compared with 
matched controls (3.7% vs. 11.2%; P = 0.012). However, all-cause mortality did not differ by group 
(2.9% vs. 4%; P = 0.943). In multivariable Cox analysis, rituximab proved independently protective of 
ASCVD (hazard ratio = 0.34, 95% confidence interval: 0.14–0.83). The lower risk of ASCVD seen with 
rituximab induction reached significance only in patient subsets of diabetes mellitus, pretransplant 
dialysis, or older age (>50 years). Rituximab induction confers a lower risk of ASCVD during the 
posttransplant period. This atheroprotective effect appears particularly beneficial in patients whose risk 
of ASCVD is heightened.
Cardiovascular disease (CVD) is the leading cause of death after kidney transplantation (KT)1, and the incidence 
of CVD is higher in KT recipients than in the general population2. Numerous studies reported that the risk of 
CVD is elevated after KT because of non-traditional risk factors such as immunologic alteration and the vari-
ous medications related to the transplantation surgery3–9. Atherosclerosis is an underlying chronic inflammatory 
condition in CVD, and the role of the immune system in the development of atherosclerosis is well descried in 
the literature10. B lymphocytes were considered to have a protective effect against atherosclerosis until nearly 
201011. However, recent experimental studies revealed opposing roles of different B cell subsets, atheroprotec-
tive B1 cells and atherogenic B2 cells12–16. Those studies also demonstrated reduced atherosclerotic plaques in 
atherosclerosis-prone mice treated with rituximab, a B cell-depleting anti-CD20 monoclonal antibody. The 
potential of B cell targeting as a treatment for atherogenesis has been suggested17, although heretofore there was 
no comparative human study of B cell depletion and atherosclerotic CVD (ASCVD).
Rituximab was introduced as an effective alternative to splenectomy for desensitization of patients requiring 
KT18. Given the excellent outcomes reported in ABO-incompatible and crossmatch-positive KT19,20, rituximab 
use in the realm of KT is increasing. Herein, we sought to explore the effects of rituximab induction on ASCVD 
in the aftermath of KT through propensity-matched analysis.
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Results
Descriptions of entire cohort. For the 1299 eligible patients, mean age was 45.3 ± 11.3 years, and there 
were 761 men (58.6%). Nine hundred forty-five patients (72.7%) underwent living donor kidney transplantation 
(LDKT), and in 126 (9.7%), retransplantation took place. One hundred ten grafts were lost including 46 deaths (7 
as cardiovascular deaths) and 77 ASCVDs occurred during a mean follow-up of 82.3 ± 35.5 months. Rituximab 
was administered preoperatively to 245 patients (18.9%; 117 ABO incompatibility, 43 crossmatch positivity, 13 
simultaneous ABO incompatibility and crossmatch positivity, and 72 high reactivity to panel antibodies). Among 
patients treated with rituximab, 167 (68.1%) were given standard doses (375 mg/m2), and 78 (31.9%) received 
reduced doses (200 mg).
Baseline characteristics before and after matching. Table 1 shows baseline characteristics of rituxi-
mab and control group patients. Before matching, there were differences in some variables, such as sex, deceased 
donor, duration of dialysis, retransplantation, tacrolimus use, pretransplant diabetes melitus (DM), baseline 
Low-density lipoprotein (LDL), biopsy-proven acute rejection (BPAR) within 1 year, and estimated glomerular 
filtration rate (eGFR) at 1 month. In 1:2 propensity score matching, 239 patients given rituximab were matched 
with 401 controls. Most variables (except BPAR within 1 year) were then balanced within the two groups (see 
Statistical analysis).
ASCVD and all-cause death in matched cohort. In the matched cohort, patients undergoing rituximab 
induction experienced only 6 ASCVD events within 8 years after KT (1 fatal myocardial infarction [MI] and 5 
percutaneous coronary revascularizations). However, 35 ASCD events were recorded in the control group (3 
fatal MIs, 1 nonfatal MI, 8 percutaneous coronary revascularizations, 4 coronary artery bypass surgeries, 8 acute 
cerebral infarctions, and 11 peripheral artery revascularizations). The cumulative rate of ASCVD was significantly 
lower in rituximab-treated patients than in controls (3.7% vs. 11.2%, P = 0.012; Fig. 1a). Seven deaths occurred in 
the rituximab group, including one cardiovascular death. Among 13 posttransplant deaths in the control group, 
three were from cardiovascular causes. During the 8-year follow-up period, rituximab-treated patients and con-
trols showed no significant difference in all-cause death (2.9% vs. 4%, P = 0.943; Fig. 1b). ASCVD events and 
causes of death in both groups are detailed in Table 2.
Serial comparison of blood pressure, renal function, and LDL. Figure 2 depicts changes over time 
in several variables known to be CVD risk factors. Although systolic blood pressure (SBP) and diastolic blood 
pressure (DBP) were higher in treated patients (vs controls) 1 month after transplantation, both levels appeared 
similar thereafter at most points in time. eGFR did not differ by group up to 1 year posttransplantation, surging 
higher in controls than in rituximab-treated patients at Years 2 and 3. LDL was higher in controls at 6 months 
only, approaching levels similar to treated patients for the duration of follow-up.
Variables








(n = 401) P
Age (years) 46.1 ± 10.5 45.1 ± 11.5 0.210 46.0 ± 10.6 44.6 ± 12.2 0.144
Sex, males 116 (47.3%) 645 (61.2%) <0.001 115 (48.1%) 207 (51.6%) 0.391
Body mass index (kg/m2) 22.3 ± 3.4 22.5 ± 3.3 0.298 22.3 ± 3.4 22.3 ± 3.5 0.754
Deceased donor 20 (8.2%) 334 (31.7%) <0.001 20 (8.4%) 40 (10.0%) 0.500
Dialysis duration (months) 4 (27) 13 (73) <0.001 4 (28) 5 (28) 0.429
Retransplantation 39 (15.9%) 87 (8.3%) <0.001 33 (13.8%) 38 (9.5%) 0.091
Use of tacrolimus (vs. cyclosporin) 237 (96.7%) 776 (73.6%) <0.001 231 (96.7%) 384 (95.8%) 0.573
Pretrasnplant alcohol use 47 (19.2%) 184 (17.5%) 0.524 47 (19.7%) 61 (15.2%) 0.146
Pretransplant smoking 47 (19.2%) 215 (20.4%) 0.669 47 (19.7%) 77 (19.2%) 0.886
Pretransplant DM 71 (29.0%) 193 (18.3%) <0.001 66 (27.6%) 105 (26.2%) 0.692
Pretransplant ASCVD history 19 (7.8%) 71 (6.7%) 0.572 18 (7.5%) 31 (7.7%) 0.927
SBP ≥ 140 mm Hg 111 (50.9%) 568 (57.5%) 0.074 109 (51.4%) 214 (56.3%) 0.251
DBP ≥ 90 mm Hg 84 (38.7%) 436 (44.2%) 0.138 83 (39.3%) 168 (44.3%) 0.240
Total cholesterol ≥ 240 (mg/dL) 6 (2.4%) 30 (2.8%) 0.733 6 (2.5%) 8 (2.0%) 0.666
LDL cholesterol ≥ 100 (mg/dL) 39 (15.9%) 323 (30.7%) <0.001 39 (16.3%) 76 (19.0%) 0.401
Use of statin 51 (20.8%) 214 (20.3%) 0.858 48 (20.1%) 90 (22.4%) 0.482
Biopsy-proven acute rejection within 1 year 64 (26.1%) 130 (12.3%) <0.001 62 (25.9%) 41 (10.2%) <0.001
eGFRa at 1 month (mL/min) 66.4 ± 24.6 62.9 ± 21.3 0.042 65.7 ± 24.3 65.1 ± 20.6 0.715
Table 1. Baseline characteristics before and after propensity score matching. aCalculated using Chronic Kidney 
Disease Epidemiology (CKD-EPI) formula. ASCVD, atherosclerotic cardiovascular disease; DBP, diastolic 
blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; KT, kidney transplantation; 
LDL, low density lipoprotein; SBP, systolic blood pressure.
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Cox proportional hazard analysis for ASCVD. In multivariable Cox analysis of matched cohort data (Table 3), 
rituximab emerged as independently protective of ASCVD developing after KT (hazard ratio [HR] = 0.34, 95% confi-
dence interval [CI]: 0.14–0.83). Other risk factors for ASCVD were maleness (HR = 2.14, 95% CI: 1.01–4.52), duration 
of dialysis (HR = 1.07, 95% CI: 1.03–1.11 [per 6 months]), retransplantation (HR = 2.90, 95% CI: 1.34–6.27), pretrans-
plant DM (HR = 3.68, 95% CI: 1.71–7.88), and pretransplant ASCVD history (HR = 4.92, 95% CI: 2.42–10.03). BPAR 
within 1 year, which differed in rituximab and control groups, was not a risk factor (HR = 0.95, 95% CI: 0.40–2.25). LDL 
cholesterol, statin use, blood pressure, and eGFR at 1 month were not associated with posttransplant ASCVD.
Subgroup analysis. Subjects of the matched cohort were stratified by pretransplant DM, sex, pretransplant 
dialysis, and age ≥ 50 years, followed by analyzing HRs of rituximab treatment for ASCVD in each subgroup 
(Fig. 3). There was no apparent interaction between any subgroup and rituximab treatment. HRs of patients with 
and without DM were 0.34 (95% CI: 0.12–0.99; P = 0.048) and 0.32 (95% CI: 0.07–1.15; P = 0.140), respectively. 
Respective HRs of male and female patients were 0.45 (95% CI: 0.17–1.18; P = 0.103) and 0.20 (95% CI: 0.03–1.57; 
P = 0.125), neither showing significance. In the presence and absence of dialysis prior to KT, HRs were 0.25 (95% 
CI: 0.07–0.82; P = 0.023) and 0.81 (95% CI: 0.15–4.31; P = 0.805), respectively; and HRs of patients beyond or less 
than 50 years old were 0.61 (95% CI: 0.20–1.88; P = 0.020) and 0.61 (95% CI: 0.20–1.88; P = 0.390), respectively.
Figure 1. Comparison of (a) ASCVD and (b) all cause death after KT by rituximab induction in the matched 







Fatal MI 1 3
Non-fatal MI 0 1
Percutaneous coronary revascularization 5 8
Coronary artery bypass surgery 0 4
Acute cerebral infarction 0 8





Gastrointestinal bleeding 1 0
Malignancy 0 1
Liver disease 1 0
Unknown 1 0
Table 2. The first ASCVD events and cause of mortality over 8 years in the matched cohort. ASCVD, 
atherosclerotic cardiovascular disease; MI, myocardial infarction.
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Discussion
In the propensity-matched analysis herein, rituximab induction significantly reduced the incidence of ASCVD 
developing after KT. Prior in vivo studies demonstrated that the use of anti-B-cell agents could be an effective 
therapeutic approach for the treatment and prevention of atherosclerosis15. Few studies have investigated the 
atheroprotective effect of rituximab using clinical data. Hsue et al.21 reported that rituximab improved endothelial 
function and reduced inflammation in patients with rheumatoid arthritis; however, they did not show a difference 
in ASCVD based on rituximab treatment.
There has been concern about cardiac complications after the use of rituximab to treat hematologic or rheu-
matologic diseases22–24. However, acute or delayed cardiac toxicity was suggested to be a result of cytokine release 
related to the infusion-related reaction rather than an aggravation of atherosclerosis. In addition, several rand-
omized controlled trials showed that there was no difference in cardiac adverse events between patients with or 
without rituximab treatment for lymphoma and rheumatoid arthritis25,26.
In the field of renal transplantation, there was only one report on rituximab and CVD. Tyden et al.27 reported 
higher mortality from MI in patients treated with rituximab than in controls. That result came from a 3-year 
follow-up of a randomized control trial, but the number of participants was small, and there was no infor-
mation about CVD risk factors. Also, the incidence of fatal MI was higher (about 10% during just 3 years of 
follow-up) compared with previous reports4,5,28. The high rate of cardiac mortality might be attributable to other 
CVD-related patient factors rather than to an adverse effect of rituximab. In fact, another recently conducted ran-
domized controlled trial has established a safety profile for rituximab in terms of serious adverse events in KT29.
Rituximab is a monoclonal antibody that globally destroys CD 20-positive B cells. However, the aforemen-
tioned experimental evidence demonstrated that rituximab reduced atherosclerosis. That atheroprotective effect 
might come from the fact that atherogenic B2 cells are a major population of the adult human B cell repertoire30. 
Another hypothesis is that because the peritoneal cavity provides rituximab resistance, resident B1 cells may be 
spared31. Although the mechanism of the atheroprotective effect of rituximab is not yet known in humans, our 
results provide an important hint for investigating the role of B cell subsets in atherogenesis.
We found that the incidence of ASCVD was relatively low in our study population. Previous large-volume 
studies in Western populations have cited CVD rates of ~15% during 4–5 years of follow-up after KT8,32, whereas 
that rate was only 6% during entire follow-up in our study. The difference might be due to dietary and lifestyle 
differences as well as the lower incidence of pretransplant ASCVD observed in Korea, compared to Western coun-
tries. Furthermore, more than 20% of patients were using statin before KT, so the mean LDL level (84.4 mg/dL) 
in our study exceeded by the mean (100 mg/dL) determined in Western studies. The relatively low incidence of 
CVD in Korean KT patients was also observed in another Korean study33 and in a previous international cohort4.
Anti-B-cell agents, including rituximab and B cell activating factor receptor antibody (belimumab), have been 
suggested as possible anti-atherogenic treatments17, but there has not yet been a clinical study. In a situation 
where the number of KTs with prior desensitization is increasing34, especially in Korea where LDKT prevails35,36, 
our results provide clinical evidence to help understand the role of rituximab in ASCVD development.
Through subgroup analysis, we extended our investigation to various CVD risk factors and their influence on 
rituximab atheroprotection. Rituximab proved significantly protective in specific clinical subsets, namely DM, 
pretransplant dialysis, and older age ( ≥ 50 years); but no HRs proved significant in the absence of these factors. 
Figure 2. Serial comparison of (a) SBP, (b) DBP, (c) eGFR and (d) LDL between the rituximab group and the 
matched controls. *P < 0.05, DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; LDL, low 
density lipoprotein; SBP, systolic blood pressure.
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In addition, gender of KT recipients had no apparent impact on ASCVD in rituximab-treated patients. Adjusted 
HRs were unobtainable for subgroups, given the low event totals. However, assessment of matched subgroups 
revealed greater rituximab atheroprotection in patients at higher risk of ASCVD. A broad multicenter study, 
perhaps utilizing a national registry, would likely yield more conclusive results.
Despite our propensity-matched analysis, retrospective feature is still limitation of our study for which the 
results should be cautiously interpreted. Also, single center design is another major limitation. Prospective and 
multicenter study should be needed.
In conclusion, this study has demonstrated that rituximab induction reduces the rate of ASCVD during post-
transplant periods. Furthermore, the atheroprotective effect of rituximab appears more advantageous for some 
KT recipients with heightened risks of ASCVD.
Methods
Patient selection. We conducted a retrospective study, accessing a database of 1,462 patients who under-
went KT at Severance Hospital, Seoul, Korea, between January 2006 and December 2015. Exclusion criteria were 
as follows: (1) age < 18 years at time of KT, (2) multiorgan transplantation, (3) rituximab use in treating anti-
body-mediated rejection after KT, and (4) acute coronary disease or patient death within 1 month after KT (2 
fatal MIs, 2 nonfatal MIs, 2 death from cerebrovascular accidents, 1 non-cardiovascular death, 1 peripheral artery 
revascularization). Ultimately, 1299 patients qualified for analysis (Fig. 4).
Data collection. We collected data on baseline characteristics of recipients and donors, lipid profiles, pre-
transplant use of statins, and BPAR within 1 year posttransplantation. SBP, DBP and eGFR were checked every 3 
months. LDL concentrations were checked every 6 months for 1 year posttransplantation and annually thereafter. 
During posttransplant periods, we checked electrocardiography at least yearly. Patients with cardiac symptoms or 
electrocardiographic abnormalities were referred to a cardiologist for further evaluation. Those undergoing coro-
nary revascularization were routinely followed by coronary angiography every 1–2 years, screening for restenosis 
or newly developed lesions. If suspected, patients were evaluated for acute cerebral infarction and peripheral arte-
rial occlusive disease. We defined ASCVD as any of the following: fatal or nonfatal MI, coronary revascularization 
(by percutaneous intervention or surgery), acute cerebral infarction, or revascularization of peripheral arterial 
occlusion (by percutaneous intervention or surgery).
Rituximab use in desensitization protocol. Indications for rituximab induction were ABO-incompatible 
or crossmatch-positive KT (living donors, both instances) and ≥ 50% panel reactive antibodies prior to KT (living 
or deceased donors). In the event of LDKT, rituximab was given within 7–14 days in advance, delivering a single 
dose of 375 mg/m2. As of August 2013, rituximab dosing for ABO-incompatible LDKT was reduced to 200 mg if 
baseline anti-donor isoagglutinin IgG titers were ≤1:12837. For deceased donor kidney transplantation, 200 mg of 
rituximab was given prior to operations as indicated. Standard regimens used at our institution for preoperative 
desensitization and postoperative immunosuppression are well described elsewhere37–39.
Variables
Univariable Cox Multivariable Coxa
HR (95% CI) P HR (95% CI) P
Age (per 5 years) 1.32 (1.15–1.53) <0.001
Sex, male 3.25 (1.59–6.63) 0.001 2.14 (1.01–4.52) 0.047
Body mass index ≥ 25 kg/m2 1.21 (0.58–2.53) 0.618
Deceased donor 1.20 (0.43–3.36) 0.735
Dialysis duration (per 6 months) 1.05 (1.02–1.09) 0.002 1.07 (1.03–1.11) <0.001
Retransplantation 2.42 (1.15–5.07) 0.019 2.90 (1.34–6.27) 0.007
Pretrasnplant alcohol use 1.37 (0.63–2.99) 0.423
Pretransplant smoking 2.11 (1.07–4.15) 0.031
Pretransplant DM 5.98 (3.15–11.33) <0.001 3.68 (1.71–7.88) 0.001
Pretransplant ASCVD history 9.29 (4.94–17.47) <0.001 4.92 (2.42–10.03) <0.001
Baseline SBP ≥ 140 mm Hg 1.15 (0.61–2.16) 0.672
Baseline DBP ≥ 90 mm Hg 0.62 (0.31–1.23) 0.169
LDL cholesterol ≥ 100 mg/dL 1.24 (0.59–2.60) 0.565
Use of statin 1.57 (0.80–3.09) 0.187
Biopsy proven acute rejection within 1 year 0.95 (0.40–2.25) 0.902
eGFRb at 1 month (per 10 mL/min) 0.97 (0.83–1.12) 0.633
Rituximab induction 0.34 (0.14–0.82) 0.017 0.34 (0.14–0.83) 0.017
Table 3. Risk factors associated with ASCVD in matched cohort. aMultivariable Cox analysis was performed 
by backward stepwise selection with P-value threshold 0.05. bCalculated using Chronic Kidney Disease 
Epidemiology (CKD-EPI) formula. ASCVD, atherosclerotic cardiovascular disease; CI, confidence interval; 
DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; KT, kidney 
transplantation; LDL, low density lipoprotein; SBP, systolic blood pressure.
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Study outcomes. We compared composite ASCVD and all-cause mortality by rituximab induction in the 
matched cohort. Because the longest follow-up period in rituximab-treated patients was 102 months, we limited 
such comparisons to 8 years after KT. We also conducted subgroup analyses, examining various patient charac-
teristics (DM, sex, required pretransplant dialysis, and age ≥ 50 years) to assess the potential influence of each in 
relation to ASCVD and rituximab use.
Statistical analysis. Propensity matching was undertaken to coordinate baseline characteristics of the 
two groups (with or without rituximab induction). Subsequent scores generated via logistic regression analysis 
included the following covariates, which differed for above groups or were known risk factors for CVD in KT 
recipients4,28: age, sex, deceased donor, duration of dialysis, retransplantation, tacrolimus use, smoking, pretrans-
plant DM, pretransplant ASCVD history, baseline LDL, and eGFR at 1 month. BPAR was not matched, because 
Figure 3. Hazard ratios for posttransplant ASCVD in clinical subgroups treated with rituximab. From matched 
cohort, subjects were stratified by DM, sex, pretransplant dialysis and 50 years of age. CI, confidence interval; 
DM, diabetes mellitus; HR, hazard ratio; KT, kidney transplantation; ASCVD, atherosclerotic cardiovascular 
disease.
Figure 4. Study population. KT, kidney transplantation; ASCVD, atherosclerotic cardiovascular disease.
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rituximab-treated patients had high risk for rejection by nature, and because BPAR had no impact on develop-
ment of ASCVD in our entire cohort. Using the nearest neighbor method, we matched patients given rituximab 
to controls at 1:2 without replacement, setting the caliper at 0.25 width. All assessments were achieved using R 
freeware v3.5.0 (R Foundation for Statistical Computing, Vienna, Austria) with MatchIt package40.
In comparing baseline characteristics of both groups before and after matching, data were expressed as 
mean ± standard deviation or median (interquartile range) for continuous variables and numbers (%) for cat-
egorical variables. Student’s t-test, Mann-Whitney U test, or chi square test was applied as needed for group 
comparisons. We used Kaplan-Meier analysis to estimate differences in probabilities of ASCVD and all-cause 
mortality according to rituximab induction and calculated P-values by log-rank test. For estimates of ASCVD, 
death from causes other than ASCVD served for censoring.
In the matched cohort, we invoked Cox proportional-hazards regression analysis to assess the relation 
between rituximab induction and posttransplant ASCVD. Multivariable Cox regression entailed backward step-
wise selection, based on covariates with P-values < 0.05 in univariable analysis. Patients were further stratified by 
known CVD risk factors such as DM, sex, pretransplant dialysis, and age ≥ 50. To retain the homogeneity of ritux-
imab and control groups, only matched pairs with or without specified variables qualified for subgroup analysis. 
Small ASCVD events in each subgroup prohibited multivariable Cox regression, so we presented only unadjusted 
HR of rituximab induction in subgroup analysis. All comparative and survival analyses relied on standard soft-
ware (SPSS v23.0; IBM, Armonk, NY, USA), setting statistical significance at P < 0.05.
Ethics statement. This study was conducted according to the principles of the Declaration of Helsinki and 
the Declaration of Istanbul. It was also approved by the Institutional Review Board of Severance Hospital, Yonsei 
University Health System (IRB No.: 4-2018-0355) with exemption for the informed consent due to the retrospec-
tive feature of this study.
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